Treatment of multifocal motor neuropathy

Current Treatment Options in Neurology

Volumn 16, Issue 2, 2014, Pages

  Jinka, Madhavi ^a   Chaudhry, Vinay ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Anti GM1 antibody; Demyelination; Immune mediated demyelinating neuropathy; Immunomodulatory agents; Immunosuppressive agents; IVIG; MMN; MMN treatment; Multifocal motor neuropathy; Partial motor conduction block; Treatment

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ABDOMINAL PAIN; ALLERGIC REACTION; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; ASTHENIA; BACKACHE; BK VIRUS INFECTION; BLOOD TOXICITY; BLOOD VESSEL OCCLUSION; BRAIN INFARCTION; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COUGHING; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE COURSE; DIZZINESS; DRUG COST; DRUG MONITORING; ELECTROPHYSIOLOGY; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HIRSUTISM; HUMAN; HYPERESTHESIA; HYPERPLASIA; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TUBULE NECROSIS; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; LYMPHOCYTOPENIA; LYMPHOMA; MALAISE; MENINGOCOCCOSIS; MOTOR NEUROPATHY; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; OPPORTUNISTIC INFECTION; PAIN; PANCYTOPENIA; PARESTHESIA; PATHOGENESIS; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; SKIN CANCER; SKIN DISEASE; STOMACH DISEASE; THROMBOCYTOPENIA; THROMBOSIS; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT DURATION; TREMOR; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

EID: 84891506795     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-013-0269-y     Document Type: Article

References (37)

1. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: Current concepts and controversies. Muscle Nerve. 2005;31:663-80.
2. Taylor BV, Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve. 2000;23:900-8.
3. Pringle CE, Belden J, Veitch JE, Brown WF. Multifocal motor neuropathy presenting as ophthalmoplegia. Muscle Nerve. 1997;20:347-51.
4. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies /Peripheral Nerve Societies guideline on management of multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15:295-301.
5. Chaudhry V, Corse AM, et al. Multifocal motor neuropathy: Electrodiagnostic features. Muscle Nerve. 1994;17:198-205.
6. Léger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study. Brain. 2001;124:145-53.
7. Cats EA, Jacobs BC, Yuki N, Tio-Gillen AP, Piepers S, Franssen H, et al. Multifocal motor neuropathy: Association of anti-GM1 IgM antibodies with clinical features. Neurology. 2010;75:1961-7.
8. Chaudhry V, Corse AM, Cornblath DR, Kuncl RW, Drachman DB. Van den Berg-Vos RM, Franssen H, Wokke JH, Van Es HW, Van den Berg LH. Multifocal motor neuropathy: Diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol. 2000;48:919-26.
9. Delmont E, Azulay JP, Giorgi R, Attarian S, Verschueren A, Uzenot D, et al. Multifocal motor neuropathy with and without conduction block: A single entity? Neurology. 2006;67:592-6.
10. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibodies and intravenous immunoglobulin for rheumatic diseases: Rationale and mechanism of action. Nat Clin Pract Rheumatol. 2007;3:262-72.
11. Piepers S, Jansen MD, Cats EA, et al. IVIg inhibits classical pathway activity and anti-GM1 IgM mediated complement deposition in MMN. J Neuroimmunol. 2010;229:256-62.
12. Yuki N, Watanabe H, Nakajima T, Spaeth PJ. IVIg blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2011;82:87-91.
13. Vucic S, Black KR, Chong PS, Cros D. Multifocal motor neuropathy: Decrease in conduction blocks and reinnervation with long-term IVIg. Neurology. 2004;63:1264-9.
14. Nobile-Orazio E, Gallia F. Multifocal motor neuropathy: Current therapies and novel strategies. Drugs. 2013;73(5):397-406
15. Eftimov F, Vermeulen M, de Haan RJ, et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst. 2009;14:93-100.
16. Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: A randomized single-blinded cross-over trial. Eur J Neurol. 2009;16:631-8.
17. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-A prospective, multi-national study. J Clin Immunol. 2006;26:177-85.
18. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet. 1995;345:365-9.
19. Piepers S, Van den Berg-Vos R, Van der Pol W-L, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: A randomized, controlled trial. Brain. 2007;130:2004-10.
20. Chaudhry V, Corse A, Cornblath DR, et al. Multifocal motor neuropathy: Response to human immune globulin. Ann Neurol. 1993;33:237-42.
21. Pestronk A, Cornblath DR, Ilyas A, et al. A treatable multi-focal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73-8.
22. Feldman EL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol. 1991;30:397-401.
23. Pestronk A, Florence J, Miller T, et al. Treatment of IgM associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485-9.
24. Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology. 2004;63:2178-9.
25. Stielgbauer K, Topakian R, Hinterberger G, Aichner FT. Beneficial effect of rituximab therapy in multifocal motor neuropathy. Neuromuscul Disord. 2009;19:473-5.
26. Michaud A, Delmont E, Jeandel PY, Desnuelle C. Improvement of severe and intravenous immunoglobulin-dependent multifocal motor neuropathy with conduction block after long-term rituximab (in French). Rev Neurol (Paris). 2011;167:916-20.
27. Rojas-Garcia R, Gallardo E, de Andrés I, et al. Chronic neuropathy with IgM anti-ganglioside antibodies: Lack of long term response to rituximab. Neurology. 2003;61:1814-6.
28. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial. Muscle Nerve. 2007;35:66-9.
29. Chaudhry V, Cornblath DR. An open label trial of rituximab (Rituxan) in multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15:196-201.
30. Markowitz CE. Interferon-beta: Mechanism of action and dosing issues. Neurology. 2007;68(24 Suppl 4):S8-S11.
31. Weinstock-Guttman B, Ransohoff RM, Kinkel P, et al. The interferon: Biological effects, mechanism of action and use in multiple sclerosis. Ann Neurol. 1995;37:7-15.
32. Martina ISJ, van Doorn PA, Schmitz PIM, et al. Chronic motor neuropathies: Response to interferonb1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry. 1999;66:197-201.
33. Van den Berg-Vos RM, Van den Berg LH, Franssen H, et al. Treatment of multifocal motor neuropathy with interferon-b1A. Neurology. 2000;54:1518-21.
34. Radziwill AJ, Botez S, Novy J, Kuntzer T. Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: An open label trial. J Peripher Nerv Syst. 2009;14:201-2.
35. Krarup C, Stewart JD, Sumner AJ, Pestronk A, Lipton SA. A syndrome of asymmetric limb weakness with motor conduction block. Neurology. 1990;40(1):118-27.
36. Nemni R, Santuccio G, Calabrese E, Galardi G, Canal N. Efficacy of cyclosporine treatment in multifocal motor neuropathy. J Neurol. 2003;250:1118-20.
37. Fitzpatrick AM, Mann CA, Barry S, et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011;16:84-91.